Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Journal Information
Full Title: Breast Cancer Res
Abbreviation: Breast Cancer Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateAll murine studies were performed following the approval of University of Colorado Anschutz Medical Campus Institutional Animal Care and Use Committee. Consent for publicationNot applicable Competing interestsJRD has stock options for OnKure, Inc. and is a paid consultant for OnKure, Inc. TMP had research support from OnKure, Inc. Authors’ information (optional)Not applicable. Competing interests JRD has stock options for OnKure, Inc. and is a paid consultant for OnKure, Inc. TMP had research support from OnKure, Inc."
"Funding This work was supported by the National Institutes of Health through the University of Colorado Cancer Center support grant 5P30CA046934-25."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025